Relief Therapeutics - eine COVID-19 Hoffnung? (Seite 378)
eröffnet am 11.03.20 17:46:44 von
neuester Beitrag 05.04.24 14:53:43 von
neuester Beitrag 05.04.24 14:53:43 von
Beiträge: 14.078
ID: 1.321.697
ID: 1.321.697
Aufrufe heute: 20
Gesamt: 2.517.962
Gesamt: 2.517.962
Aktive User: 0
ISIN: CH1251125998 · WKN: A3EFB5 · Symbol: RLF
1,2850
CHF
+1,98 %
+0,0250 CHF
Letzter Kurs 17:30:49 SIX Swiss (CHF)
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5285 | +36,60 | |
| 0,6000 | +25,26 | |
| 4,5700 | +24,18 | |
| 1,8300 | +23,65 | |
| 0,7600 | +21,68 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7008 | -15,56 | |
| 0,7603 | -15,56 | |
| 2,8600 | -19,21 | |
| 27,00 | -49,30 | |
| 3,4200 | -53,53 |
Beitrag zu dieser Diskussion schreiben
Feedback
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)
Lawsuit alleges multiple breaches of Collaboration Agreement
Geneva, Switzerland, October 7, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that it has filed a lawsuit against NeuroRx, Inc. and its Chief Executive Officer, Dr. Jonathan Javitt, for multiple breaches of the Collaboration Agreement between Relief and NeuroRx relating to the development and commercialization of RLF-100™ (aviptadil). The complaint was filed in the Supreme Court of the State of New York in Manhattan.
The complaint alleges that the defendants are in breach of numerous provisions of the Collaboration Agreement, including without limitation (i) by failing to provide Relief with the full data set from NeuroRx's recently completed phase 2b/3 clinical trial evaluating IV RLF-100™ (aviptadil) for the treatment of acute respiratory failure due to COVID-19, which data and information are required to be provided to Relief by NeuroRx under the Collaboration Agreement and which data and information are required for Relief to seek approval to commercialize the product in Europe, (ii) by failing to allow Relief, despite multiple requests, to conduct a forensic audit of NeuroRx's books and records to determine how the funds that Relief provided to NeuroRx were actually used, (iii) by entering into multiple agreements relating to the development of the product subject to the collaboration without Relief's consent, as required under the Collaboration Agreement, (iv) by engaging in commercialization efforts in territories outside the purview of NeuroRx's territory under the Collaboration Agreement, and (v) by developing additional COVID-19 treatments in violation of the exclusivity provisions of the Collaboration Agreement. The suit also alleges, among other matters, breaches of the covenant of good faith and fair dealing and tortious interference with prospective economic advantage. The Complaint, among other remedies, seeks damages, an order compelling defendants to comply with multiple provisions of the Collaboration Agreement, and a declaration directing NeuroRx to deliver the entire data set from the Phase 2b/3 clinical trial of intravenously-administering aviptadil to Relief.
"We are disappointed that NeuroRx has continued to refuse to ameliorate their breaches of the Collaboration Agreement," stated Jack Weinstein, Chief Financial Officer and Treasurer of Relief. "While we continue to hope to settle these matters with NeuroRx, we are compelled to bring this action to preserve our rights under the Collaboration Agreement and to allow us to continue to develop RLF-100™ (aviptadil) in a timely manner for the treatment of acute respiratory failure due to COVID-19 in our territories."
Lawsuit alleges multiple breaches of Collaboration Agreement
Geneva, Switzerland, October 7, 2021 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that it has filed a lawsuit against NeuroRx, Inc. and its Chief Executive Officer, Dr. Jonathan Javitt, for multiple breaches of the Collaboration Agreement between Relief and NeuroRx relating to the development and commercialization of RLF-100™ (aviptadil). The complaint was filed in the Supreme Court of the State of New York in Manhattan.
The complaint alleges that the defendants are in breach of numerous provisions of the Collaboration Agreement, including without limitation (i) by failing to provide Relief with the full data set from NeuroRx's recently completed phase 2b/3 clinical trial evaluating IV RLF-100™ (aviptadil) for the treatment of acute respiratory failure due to COVID-19, which data and information are required to be provided to Relief by NeuroRx under the Collaboration Agreement and which data and information are required for Relief to seek approval to commercialize the product in Europe, (ii) by failing to allow Relief, despite multiple requests, to conduct a forensic audit of NeuroRx's books and records to determine how the funds that Relief provided to NeuroRx were actually used, (iii) by entering into multiple agreements relating to the development of the product subject to the collaboration without Relief's consent, as required under the Collaboration Agreement, (iv) by engaging in commercialization efforts in territories outside the purview of NeuroRx's territory under the Collaboration Agreement, and (v) by developing additional COVID-19 treatments in violation of the exclusivity provisions of the Collaboration Agreement. The suit also alleges, among other matters, breaches of the covenant of good faith and fair dealing and tortious interference with prospective economic advantage. The Complaint, among other remedies, seeks damages, an order compelling defendants to comply with multiple provisions of the Collaboration Agreement, and a declaration directing NeuroRx to deliver the entire data set from the Phase 2b/3 clinical trial of intravenously-administering aviptadil to Relief.
"We are disappointed that NeuroRx has continued to refuse to ameliorate their breaches of the Collaboration Agreement," stated Jack Weinstein, Chief Financial Officer and Treasurer of Relief. "While we continue to hope to settle these matters with NeuroRx, we are compelled to bring this action to preserve our rights under the Collaboration Agreement and to allow us to continue to develop RLF-100™ (aviptadil) in a timely manner for the treatment of acute respiratory failure due to COVID-19 in our territories."
https://patientdaily.com/stories/608792808-covid-19-patients…
COVID-19 patients, families launch petition to convince FDA to approve promising drug
A petition has been launched pleading for the FDA to authorize Aviptadil for COVID treatments.
The Change.org petition has over 3,900 signers so far out of a goal of 5,000.
COVID-19 patients, families launch petition to convince FDA to approve promising drug
A petition has been launched pleading for the FDA to authorize Aviptadil for COVID treatments.
The Change.org petition has over 3,900 signers so far out of a goal of 5,000.
Antwort auf Beitrag Nr.: 69.523.815 von Schumlim999 am 06.10.21 19:26:23Gemuted lebt es ich leichter …
Antwort auf Beitrag Nr.: 69.523.719 von CnfsdCat am 06.10.21 19:17:13Danke wiedermal für Deinen super Beitrag hier
Trading Spotlight
Es braucht keine negativen News um zu verstehen dass der Bums nichts taugt.
Und keine Sorge, der Boden ist noch lange nicht erreicht, die 0,0X werden bald zu sehen sein 🔥🔥🔥
Und keine Sorge, der Boden ist noch lange nicht erreicht, die 0,0X werden bald zu sehen sein 🔥🔥🔥
Antwort auf Beitrag Nr.: 69.522.585 von schlafmuetze29 am 06.10.21 17:48:41😂 irgendwo muss es auch einen Boden geben, schlimm genug wo der Kurs ohne fundamental negative News hingerutscht ist. Die beiden Parteien haben da schon was angerichtet und diesen Kurs billigend in kauf genommen 🤦🏻♂️ hoffen wir, dass es das wert wart
Antwort auf Beitrag Nr.: 69.516.435 von SL2020 am 06.10.21 10:43:24
Jetzt hat RLF sogar ohne Verlust geschlossen.... wissen Insider wieder mehr, wie diese aussergewöhnliche Stärke so plötzlich zu Stande kommt? 🤪,......morgen vielleicht 1%Gewinn?
Zitat von SL2020: Abwarten…. Der Tag dauert noch….. denke -4% werdens noch…….. unglaublich echt 🤮
Jetzt hat RLF sogar ohne Verlust geschlossen.... wissen Insider wieder mehr, wie diese aussergewöhnliche Stärke so plötzlich zu Stande kommt? 🤪,......morgen vielleicht 1%Gewinn?
Antwort auf Beitrag Nr.: 69.516.627 von TomR7 am 06.10.21 10:58:23Bei dieser Petition lief lange Zeit nichts mehr, seit gestern kommt wieder Bewegung rein. Habe auch unterschrieben und hoffe natürlich das bringt etwas.
Immerhin startet Acer mal durch, bei uns leider (noch?) nicht
Durchsuchen
Relief Therapeutics - eine COVID-19 Hoffnung?
